WO2024050421A2 - Molécules de liaison à l'antigène ciblant la protéine 1 de mort cellulaire programmée (pd-1) - Google Patents
Molécules de liaison à l'antigène ciblant la protéine 1 de mort cellulaire programmée (pd-1) Download PDFInfo
- Publication number
- WO2024050421A2 WO2024050421A2 PCT/US2023/073172 US2023073172W WO2024050421A2 WO 2024050421 A2 WO2024050421 A2 WO 2024050421A2 US 2023073172 W US2023073172 W US 2023073172W WO 2024050421 A2 WO2024050421 A2 WO 2024050421A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- amino acid
- acid sequence
- lcdr2
- hcdr1
- Prior art date
Links
- 101710089372 Programmed cell death protein 1 Proteins 0.000 title claims abstract description 96
- 102100040678 Programmed cell death protein 1 Human genes 0.000 title claims abstract description 95
- 230000027455 binding Effects 0.000 title claims abstract description 55
- 239000000427 antigen Substances 0.000 title claims abstract description 45
- 102000036639 antigens Human genes 0.000 title claims abstract description 44
- 108091007433 antigens Proteins 0.000 title claims abstract description 44
- 230000008685 targeting Effects 0.000 title description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 273
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 262
- 229920001184 polypeptide Polymers 0.000 claims abstract description 260
- 238000000034 method Methods 0.000 claims abstract description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 32
- 239000012634 fragment Substances 0.000 claims abstract description 22
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 22
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 22
- 239000002157 polynucleotide Substances 0.000 claims abstract description 22
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 21
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 239000013598 vector Substances 0.000 claims abstract description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 1759
- 238000006467 substitution reaction Methods 0.000 claims description 100
- 235000001014 amino acid Nutrition 0.000 claims description 83
- 108010032595 Antibody Binding Sites Proteins 0.000 claims description 72
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 54
- 229910052717 sulfur Inorganic materials 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 25
- 229910052731 fluorine Inorganic materials 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 229940124597 therapeutic agent Drugs 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 235000018102 proteins Nutrition 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 230000001363 autoimmune Effects 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 230000011664 signaling Effects 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000002105 nanoparticle Substances 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 8
- 206010025135 lupus erythematosus Diseases 0.000 claims description 8
- 229910052698 phosphorus Inorganic materials 0.000 claims description 8
- 206010043207 temporal arteritis Diseases 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims description 6
- 102400000739 Corticotropin Human genes 0.000 claims description 6
- 101800000414 Corticotropin Proteins 0.000 claims description 6
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 6
- 206010019939 Herpes gestationis Diseases 0.000 claims description 6
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 6
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 6
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 6
- 229960000258 corticotropin Drugs 0.000 claims description 6
- 201000001981 dermatomyositis Diseases 0.000 claims description 6
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims description 6
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims description 6
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 5
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000001965 increasing effect Effects 0.000 claims description 5
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims description 4
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims description 4
- 102000003954 Autophagy-Related Proteins Human genes 0.000 claims description 4
- 108010082399 Autophagy-Related Proteins Proteins 0.000 claims description 4
- 208000005024 Castleman disease Diseases 0.000 claims description 4
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 4
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 claims description 4
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 208000021866 Dressler syndrome Diseases 0.000 claims description 4
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims description 4
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims description 4
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims description 4
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims description 4
- 208000031814 IgA Vasculitis Diseases 0.000 claims description 4
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
- 208000012309 Linear IgA disease Diseases 0.000 claims description 4
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 4
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 4
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 claims description 4
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 4
- 206010034277 Pemphigoid Diseases 0.000 claims description 4
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 4
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 claims description 4
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 4
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims description 4
- 206010042276 Subacute endocarditis Diseases 0.000 claims description 4
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 4
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims description 4
- 206010051526 Tolosa-Hunt syndrome Diseases 0.000 claims description 4
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 claims description 4
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 claims description 4
- 206010046851 Uveitis Diseases 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 239000003435 antirheumatic agent Substances 0.000 claims description 4
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims description 4
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims description 4
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- 208000002557 hidradenitis Diseases 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 4
- 201000008319 inclusion body myositis Diseases 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 206010063344 microscopic polyangiitis Diseases 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 201000005580 palindromic rheumatism Diseases 0.000 claims description 4
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000008467 subacute bacterial endocarditis Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000005784 autoimmunity Effects 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 2
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 claims description 2
- AEMOLEFTQBMNLQ-AZLKCVHYSA-N (2r,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-AZLKCVHYSA-N 0.000 claims description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 2
- QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 2
- 206010001935 American trypanosomiasis Diseases 0.000 claims description 2
- 208000028185 Angioedema Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 206010003267 Arthritis reactive Diseases 0.000 claims description 2
- 206010071155 Autoimmune arthritis Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims description 2
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims description 2
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims description 2
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 claims description 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 229940123208 Biguanide Drugs 0.000 claims description 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 201000006390 Brachial Plexus Neuritis Diseases 0.000 claims description 2
- 201000002829 CREST Syndrome Diseases 0.000 claims description 2
- 208000024699 Chagas disease Diseases 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 208000010007 Cogan syndrome Diseases 0.000 claims description 2
- 208000011038 Cold agglutinin disease Diseases 0.000 claims description 2
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims description 2
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 claims description 2
- 206010011258 Coxsackie myocarditis Diseases 0.000 claims description 2
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 229930105110 Cyclosporin A Natural products 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims description 2
- 206010015226 Erythema nodosum Diseases 0.000 claims description 2
- 208000000289 Esophageal Achalasia Diseases 0.000 claims description 2
- 208000004332 Evans syndrome Diseases 0.000 claims description 2
- 108010011459 Exenatide Proteins 0.000 claims description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- YCISZOVUHXIOFY-HKXOFBAYSA-N Halopredone acetate Chemical compound C1([C@H](F)C2)=CC(=O)C(Br)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@](OC(C)=O)(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O YCISZOVUHXIOFY-HKXOFBAYSA-N 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 206010019263 Heart block congenital Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 2
- 206010021263 IgA nephropathy Diseases 0.000 claims description 2
- 208000021330 IgG4-related disease Diseases 0.000 claims description 2
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 2
- 208000031781 Immunoglobulin G4 related sclerosing disease Diseases 0.000 claims description 2
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108010073961 Insulin Aspart Proteins 0.000 claims description 2
- 108010089308 Insulin Detemir Proteins 0.000 claims description 2
- 108010057186 Insulin Glargine Proteins 0.000 claims description 2
- 108010065920 Insulin Lispro Proteins 0.000 claims description 2
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims description 2
- 229940122355 Insulin sensitizer Drugs 0.000 claims description 2
- 108010005716 Interferon beta-1a Proteins 0.000 claims description 2
- 108010005714 Interferon beta-1b Proteins 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 206010022557 Intermediate uveitis Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 208000011200 Kawasaki disease Diseases 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims description 2
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims description 2
- 206010024434 Lichen sclerosus Diseases 0.000 claims description 2
- 108010019598 Liraglutide Proteins 0.000 claims description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims description 2
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 claims description 2
- 208000016604 Lyme disease Diseases 0.000 claims description 2
- 208000027530 Meniere disease Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 claims description 2
- 208000024599 Mooren ulcer Diseases 0.000 claims description 2
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 206010029229 Neuralgic amyotrophy Diseases 0.000 claims description 2
- 206010071579 Neuronal neuropathy Diseases 0.000 claims description 2
- 206010030136 Oesophageal achalasia Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 208000025174 PANDAS Diseases 0.000 claims description 2
- 206010053869 POEMS syndrome Diseases 0.000 claims description 2
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- HYRKAAMZBDSJFJ-LFDBJOOHSA-N Paramethasone acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]2(C)C[C@@H]1O HYRKAAMZBDSJFJ-LFDBJOOHSA-N 0.000 claims description 2
- 208000004788 Pars Planitis Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 208000000766 Pityriasis Lichenoides Diseases 0.000 claims description 2
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 2
- 208000004347 Postpericardiotomy Syndrome Diseases 0.000 claims description 2
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 claims description 2
- HUMXXHTVHHLNRO-KAJVQRHHSA-N Prednisolone tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O HUMXXHTVHHLNRO-KAJVQRHHSA-N 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 2
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 2
- 206010039705 Scleritis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 229940100389 Sulfonylurea Drugs 0.000 claims description 2
- 208000002286 Susac Syndrome Diseases 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 2
- 241000223109 Trypanosoma cruzi Species 0.000 claims description 2
- 108700036309 Type I Plasminogen Deficiency Proteins 0.000 claims description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 claims description 2
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 claims description 2
- 208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 claims description 2
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 claims description 2
- 229960002632 acarbose Drugs 0.000 claims description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 2
- 201000000621 achalasia Diseases 0.000 claims description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 229960001667 alogliptin Drugs 0.000 claims description 2
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 2
- 206010002022 amyloidosis Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000006424 autoimmune oophoritis Diseases 0.000 claims description 2
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 claims description 2
- 206010071578 autoimmune retinopathy Diseases 0.000 claims description 2
- 208000029407 autoimmune urticaria Diseases 0.000 claims description 2
- 230000003376 axonal effect Effects 0.000 claims description 2
- 206010003882 axonal neuropathy Diseases 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- 229960002537 betamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 208000024376 chronic urticaria Diseases 0.000 claims description 2
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 229960002436 cladribine Drugs 0.000 claims description 2
- 201000004395 congenital heart block Diseases 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 claims description 2
- 229960003290 cortisone acetate Drugs 0.000 claims description 2
- 201000003278 cryoglobulinemia Diseases 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- 229960003657 dexamethasone acetate Drugs 0.000 claims description 2
- 229950000812 dexamethasone palmitate Drugs 0.000 claims description 2
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 claims description 2
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims description 2
- 208000019479 dysautonomia Diseases 0.000 claims description 2
- 201000002491 encephalomyelitis Diseases 0.000 claims description 2
- 230000002327 eosinophilic effect Effects 0.000 claims description 2
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 claims description 2
- 229950010170 epalrestat Drugs 0.000 claims description 2
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 claims description 2
- 229960001519 exenatide Drugs 0.000 claims description 2
- 208000002980 facial hemiatrophy Diseases 0.000 claims description 2
- 229960000556 fingolimod Drugs 0.000 claims description 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 2
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 claims description 2
- 229960003336 fluorocortisol acetate Drugs 0.000 claims description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
- 208000018090 giant cell myocarditis Diseases 0.000 claims description 2
- 229960003776 glatiramer acetate Drugs 0.000 claims description 2
- 229960004580 glibenclamide Drugs 0.000 claims description 2
- 229960000346 gliclazide Drugs 0.000 claims description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 2
- 229960004346 glimepiride Drugs 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 2
- 229950004611 halopredone acetate Drugs 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960004204 hydrocortisone sodium phosphate Drugs 0.000 claims description 2
- 229960001401 hydrocortisone sodium succinate Drugs 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 201000006362 hypersensitivity vasculitis Diseases 0.000 claims description 2
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 claims description 2
- 229960001195 imidapril Drugs 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 2
- 229960004717 insulin aspart Drugs 0.000 claims description 2
- 229960003948 insulin detemir Drugs 0.000 claims description 2
- 229960002869 insulin glargine Drugs 0.000 claims description 2
- 229960002068 insulin lispro Drugs 0.000 claims description 2
- 230000003914 insulin secretion Effects 0.000 claims description 2
- 229960004461 interferon beta-1a Drugs 0.000 claims description 2
- 229960003161 interferon beta-1b Drugs 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 claims description 2
- 201000011486 lichen planus Diseases 0.000 claims description 2
- 206010071570 ligneous conjunctivitis Diseases 0.000 claims description 2
- 229960002701 liraglutide Drugs 0.000 claims description 2
- 108010004367 lixisenatide Proteins 0.000 claims description 2
- 229960001093 lixisenatide Drugs 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- 229940041033 macrolides Drugs 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003105 metformin Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960004584 methylprednisolone Drugs 0.000 claims description 2
- 229960001293 methylprednisolone acetate Drugs 0.000 claims description 2
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 claims description 2
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 claims description 2
- 229960003404 mexiletine Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- 229950000844 mizoribine Drugs 0.000 claims description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 201000003631 narcolepsy Diseases 0.000 claims description 2
- 229960000698 nateglinide Drugs 0.000 claims description 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 208000004235 neutropenia Diseases 0.000 claims description 2
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 claims description 2
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 claims description 2
- 201000005737 orchitis Diseases 0.000 claims description 2
- 229960000865 paramethasone acetate Drugs 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 229960005095 pioglitazone Drugs 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- 229960002800 prednisolone acetate Drugs 0.000 claims description 2
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 claims description 2
- 229960002943 prednisolone sodium phosphate Drugs 0.000 claims description 2
- 229960002176 prednisolone sodium succinate Drugs 0.000 claims description 2
- FKKAEMQFOIDZNY-CODXZCKSSA-M prednisolone sodium succinate Chemical compound [Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 FKKAEMQFOIDZNY-CODXZCKSSA-M 0.000 claims description 2
- 229960004259 prednisolone tebutate Drugs 0.000 claims description 2
- 208000018290 primary dysautonomia Diseases 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 239000000186 progesterone Substances 0.000 claims description 2
- 229960003387 progesterone Drugs 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 208000009169 relapsing polychondritis Diseases 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- 229960004034 sitagliptin Drugs 0.000 claims description 2
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 208000009174 transverse myelitis Diseases 0.000 claims description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 2
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims description 2
- 229960001254 vildagliptin Drugs 0.000 claims description 2
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims description 2
- 229960001729 voglibose Drugs 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 abstract description 2
- -1 homocitruline Chemical compound 0.000 description 18
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 15
- 230000000670 limiting effect Effects 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 10
- 102000048362 human PDCD1 Human genes 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 108091008874 T cell receptors Proteins 0.000 description 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000002998 immunogenetic effect Effects 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 108010074708 B7-H1 Antigen Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 5
- 230000008484 agonism Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 108091035707 Consensus sequence Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 4
- 229940122544 PD-1 agonist Drugs 0.000 description 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000001270 agonistic effect Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 230000009824 affinity maturation Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000012575 bio-layer interferometry Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000005094 computer simulation Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 2
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 2
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 2
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 2
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 2
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 2
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 102000013264 Interleukin-23 Human genes 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001371 alpha-amino acids Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091028075 Circular RNA Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229940124060 PD-1 antagonist Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940126530 T cell activator Drugs 0.000 description 1
- 206010071574 Testicular autoimmunity Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000009394 selective breeding Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- PD-1 Programmed cell death protein 1
- IBDs inflammatory bowel diseases
- the disclosure provided herein is based, in part, on the discovery of polypeptides that specifically bind to PD-1. Accordingly, the disclosure generally relates to polypeptides (e.g., antibodies), compositions (e.g., pharmaceutical compositions) and methods that are useful for binding to PD-1 and, in some embodiments, modulating (e.g., increasing, enhancing) PD-1 signaling (e.g., in vivo).
- polypeptides e.g., antibodies
- compositions e.g., pharmaceutical compositions
- modulating e.g., increasing, enhancing
- PD-1 signaling e.g., in vivo
- polypeptides e.g., antibodies and antigen binding fragments thereof
- PD-1 e.g., full-length human PD-1 - 1 - 3820371.v1 5708.1067001 or a variant thereof.
- polypeptides disclosed herein function as agonists of PD-1 signaling.
- the disclosure provides, among other things, a polypeptide comprising a paratope that is substantially similar to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:
- the disclosure also provides, among other things, a polypeptide comprising: an immunoglobulin heavy chain variable domain (VH) amino acid sequence comprising a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2) and a heavy chain complementarity determining region 3 (HCDR3) that are substantially similar to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216; and an immunoglobulin light chain variable domain (VL) amino acid sequence comprising a light chain complementarity determining region 1 (LCDR1), a light chain complementarity determining region 2 (LCDR2) and a light chain complementarity determining region 3 (LCDR3) that are substantially similar to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in any of SEQ ID NO
- a polypeptide comprises the HCDR1, HCDR2 and HCDR3, and the LCDR1, LCDR2 and LCDR3, of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); - 4 - 3820371.v1 5708.1067001 SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:
- a polypeptide comprises a paratope that is identical to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:67 (AB-9);
- the disclosure also provides, among other things, a polypeptide comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:227, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:229, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-65); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:148, an HCDR3 comprising the amino acid sequence of SEQ ID NO:228, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-75);
- the disclosure further provides, among other things, a polypeptide that comprises a VH comprising: a) the amino acid sequence of SEQ ID NO:2, wherein: X 1 is L or F; X 2 is G, A, S, T or P; X3 is V, F or absent; X 4 is S or absent; X 5 is S, G, N or absent; X6 is F, D, I, T, S or V; X 7 is A, S, R, N or K; X 8 is A, H or T; X9 is M or I; X10 is S or G; X 11 is S or G; X12 is S or G; X13 is G, D, A, R, E or T; X 14 is H, D, A, S or N; X 15 is A or I; X16 is H, A, I, Y or V; X 17 is S or D; X 18 is Y, T or H; or - 21 - 3820371.v1 5708.
- a polypeptide comprises: a) a VL comprising the amino acid sequence of SEQ ID NO:59, wherein: X 20 is H, Q, A, S, Y, R or K; or X 21 is A, S, T or G, or any combination of the foregoing; or b) a V L comprising the amino acid sequence of SEQ ID NO:70, wherein: X 46 is V, I or F; X47 is V, K, T, M, R or L; X48 is P or T; X 49 is P or Q; X50 is P, F or S; X51 is P or S; X 52 is V or L; X 53 is H or Q; X54 is D, G or Y; X 55 is D, T or N; X 56 is C, Y or A; - 23 - 3820371.v1 5708.1067001 X57 is K or E; X58 is M, T, I or S; X 59
- a polypeptide disclosed herein modulates (e.g., increases, enhances, promotes) binding between PD-1 and one or more of its ligands, such as PD-L1 and PD-L2. In some embodiments, a polypeptide disclosed herein modulates (e.g., increases, enhances, promotes) PD-1-mediated signaling in vitro, ex vivo, and/or in vivo.
- a polypeptide is a fusion protein.
- the disclosure provides a polynucleotide encoding a polypeptide disclosed herein, a vector comprising such polynucleotide, and/or a host cell comprising such polynucleotide and/or vector.
- the disclosure provides methods of treating a patient and/or subject in need thereof (e.g., a subject having a disease or condition, such as an inflammatory disease or condition), comprising administering to the subject an effective amount (e.g., a therapeutically effective amount) of one or more of any of the polypeptides disclosed herein and/or a composition (e.g., pharmaceutical composition) comprising one or more of any of the polypeptides disclosed herein.
- the disclosure provides a method of modulating (e.g., increasing, enhancing, promoting) PD-1-mediated signaling in a cell (e.g., a cell in a subject), comprising contacting the cell with a composition comprising a polypeptide disclosed herein or a composition (e.g., pharmaceutical composition) comprising a polypeptide disclosed herein.
- FIG.1 depicts the amino acid sequence of human programmed cell death-1 (PD- 1) (SEQ ID NO:1). Epitope residues predicted to be bound by one or more antibodies disclosed herein are indicated by asterisks.
- FIGs.2A and 2B depict an alignment of non-limiting examples of heavy chain variable domain (VH) amino acid sequences that are useful in polypeptides as disclosed herein.
- VH heavy chain variable domain
- HCDR heavy chain complementarity determining region amino acid sequences as determined by ImMunoGeneTics (IMGT) numbering (www.imgt.org/IMGTScientificChart/Nomenclature/IMGT-FRCDRdefinition.html, also accessible at www.imgt.org/) are indicated using bold letters within boxed portions of the sequences. Green highlighting indicates non-limiting examples of variable residues (designated throughout this disclosure by “Xn”) in the depicted sequences. Also see a first VH consensus sequence (SEQ ID NO:2) in Table 4. “*” indicates predicted paratope residues.
- FIGs.3A-3D depict an alignment of non-limiting examples of VH amino acid sequences that are useful in polypeptides as disclosed herein.
- the HCDR amino acid sequences as determined by IMGT numbering are indicated using bold letters within boxed portions of the sequences.
- Green highlighting indicates non-limiting examples of variable residues (designated throughout this disclosure by “Xn”) in the depicted sequences.
- Xn variable residues
- FIGs.4A and 4B depict an alignment of non-limiting examples of light chain variable domain (VL) amino acid sequences that are useful in polypeptides as disclosed herein.
- VL light chain variable domain
- LCDR light chain complementarity determining region
- Green highlighting indicates non-limiting examples of variable residues (designated throughout this disclosure by “Xn”) in the depicted sequences.
- Xn variable residues
- FIGs.5A-5D depict an alignment of non-limiting examples of V L amino acid sequences that are useful in polypeptides as disclosed herein.
- the LCDR amino acid sequences as determined by IMGT numbering are indicated using bold letters within boxed portions of the sequences.
- Green highlighting indicates non-limiting examples of variable residues (designated throughout this disclosure by “Xn”) in the depicted sequences.
- Xn variable residues
- FIGs.6A-6D depict structural validation of an example de-novo generated PD-1- agonizing antibody disclosed herein (AB-49).
- FIG.6A shows the structure of PD-1 (light gray surface) with the desired epitope region shown in dark gray.
- FIG.6B shows a computationally-generated model of AB-49 bound to the desired epitope on PD-1.
- FIG.6C shows a crystal structure of the Fab fragment of AB-49 in FIG.6B alone, solved at 2.46 ⁇ resolution.
- FIG.6D shows superpositions of the Fab-alone crystal structure and the corresponding computational model.
- Polypeptides that Specifically Bind Programmed Cell Death-1 are provided herein, among other things, are polypeptides that specifically bind to PD-1 (e.g., full-length human PD-1, e.g., SEQ ID NO: 1).
- a polypeptide modulates (e.g., increases, enhances, promotes) binding between PD-1 and one or more of its ligands, PD-L1 and PD-L2 and/or modulates (e.g., increases, enhances, promotes) PD-1-mediated signaling.
- polypeptide “peptide” or “protein” denotes a polymer of at least two amino acids covalently linked by an amide bond, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation).
- a protein, peptide or polypeptide can comprise any suitable L-and/or D-amino acid, for example, common ⁇ -amino acids (e.g., alanine, glycine, valine), non- ⁇ -amino acids (e.g., ⁇ -alanine, 4-aminobutyric acid, 6- aminocaproic acid, sarcosine, statine), and unusual amino acids (e.g., citrulline, homocitruline, homoserine, norleucine, norvaline, ornithine).
- the amino, carboxyl and/or other functional groups on a peptide can be free (e.g., unmodified) or protected with a suitable protecting group.
- Suitable protecting groups for amino and carboxyl groups, and methods for adding or removing protecting groups are known in the art and are disclosed in, for example, Green and Wuts, “Protecting Groups in Organic Synthesis,” John Wiley and Sons, 1991.
- the functional groups of a protein, peptide or polypeptide can also be derivatized (e.g., alkylated) or labeled (e.g., with a detectable label, such as a fluorogen or a hapten) using methods known in the art.
- a protein, peptide or polypeptide can comprise one or more modifications (e.g., amino acid linkers, acylation, acetylation, amidation, methylation, terminal modifiers (e.g., cyclizing modifications), N-methyl- ⁇ -amino group substitution), if desired.
- a protein, peptide or polypeptide can be an analog of a known and/or naturally-occurring peptide, for example, a peptide analog having conservative amino acid residue substitution(s).
- PD-1 includes full-length PD-1 proteins (e.g., having the amino acid sequence of SEQ ID NO:1 (GenBank: AIC54874.1) or homologs thereof) and truncated forms thereof, mutant and engineered versions of full-length and truncated
- a polypeptide disclosed herein binds to a PD-1 protein comprising the amino acid sequence of SEQ ID NO:1. In some embodiments, a polypeptide binds to a PD-1 protein comprising the amino acid sequence of SEQ ID NO:1 and a PD-1 protein comprising the amino acid sequence of SEQ ID NO:205. [0035] In some embodiments, a polypeptide disclosed herein binds to one or more epitope residues of a PD-1 protein (e.g., one or more epitope residues in SEQ ID NO:1).
- a polypeptide is capable of binding to one or more epitope residues in the full-length human PD-1, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 residues of the full-length human PD-1.
- a polypeptide is capable of binding to one or more epitope residues (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or all 16 residues) selected from D48, N49, T51, T53, P83, E84, R96, V97, T98, L100, P101, N102, D105, H107, S109 and V111 of SEQ ID NO:1.
- a polypeptide binds to a mutant, engineered or modified form of PD-1.
- the mutant, engineered or modified form of PD-1 comprises an amino acid sequence that has at least about 90% sequence identity to a wildtype full-length PD-1 sequence (e.g., SEQ ID NO:1), for example, having at least about: 91%, - 28 - 3820371.v1 5708.1067001 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to a wildtype full-length PD-1 sequence.
- sequence identity is about: 90-99.9%, 90-99.8%, 92-99.8%, 92-99.6%, 94- 99.6%, 94-99.5%, 95-99.5%, 95-99.4%, 96-99.4%, 96-99.2%, 97-99.2% or 97-99%.
- sequence identity refers to the extent to which two nucleotide sequences, or two amino acid sequences, have the same residues at the same positions when the sequences are aligned to achieve a maximal level of identity, expressed as a percentage. For sequence alignment and comparison, typically one sequence is designated as a reference sequence, to which a test sequence is compared.
- sequence identity is expressed as the percentage of positions across the entire length of the reference sequence where the reference and test sequences share the same nucleotide or amino acid upon alignment of the reference and test sequences to achieve a maximal level of identity.
- two sequences are considered to have 70% sequence identity when, upon alignment to achieve a maximal level of identity, the test sequence has the same nucleotide or amino acid residue at 70% of the same positions over the entire length of the reference sequence.
- Alignment of sequences for comparison to achieve maximal levels of identity can be readily performed by a person of ordinary skill in the art using an appropriate alignment method or algorithm. In some instances, the alignment can include introduced gaps to provide for the maximal level of identity. Examples include the local homology algorithm of Smith & Waterman, Adv. Appl.
- the sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.
- a commonly used tool for determining percent sequence identity is Protein Basic Local Alignment Search Tool (BLASTP) available through National Center for Biotechnology Information, National - 29 - 3820371.v1 5708.1067001 Library of Medicine, of the United States National Institutes of Health. (Altschul et al., 1990).
- BLASTP Protein Basic Local Alignment Search Tool
- the disclosure provides a polypeptide that specifically binds PD-1.
- a polypeptide comprises a paratope that is substantially similar to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:67 (AB-9); SEQ ID NO:10 and
- a polypeptide comprises a paratope that is substantially similar to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); or SEQ ID NO:214 and SEQ ID NO:226 (AB-74), or any combination of the foregoing.
- a polypeptide comprises a paratope that is substantially similar to a paratope of an antibody, wherein the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO:206 and a VL comprising the amino acid sequence of SEQ ID NO:217 (AB-65).
- a polypeptide comprises a paratope that is substantially similar to a paratope of an antibody, wherein the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO:215, and a V L comprising the amino acid sequence of SEQ ID NO:104 (AB-75).
- a polypeptide comprises a paratope that is substantially similar to a paratope of an antibody, wherein the antibody comprises a V H comprising the - 32 - 3820371.v1 5708.1067001 amino acid sequence of SEQ ID NO:214, and a VL comprising the amino acid sequence of SEQ ID NO:226 (AB-74).
- the disclosure provides a polypeptide that specifically binds PD-1.
- a polypeptide comprises a paratope that is identical to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:67 (AB-9); SEQ ID NO:
- a polypeptide comprises a paratope that is identical to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); or SEQ ID NO:214 and SEQ ID NO:226 (AB-74), or any combination of the foregoing.
- a polypeptide comprises a paratope that is identical to a paratope of an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:206 and a VL comprising the amino acid sequence of SEQ ID NO:217 (AB-65).
- a polypeptide comprises a paratope that is identical to a paratope of an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:215, and a VL comprising the amino acid sequence of SEQ ID NO:104 (AB-75).
- a polypeptide comprises a paratope that is identical to a paratope of an antibody comprising a V H comprising the amino acid sequence of SEQ ID NO:214, and a VL comprising the amino acid sequence of SEQ ID NO:226 (AB-74).
- FIGs.3A-3D for paratope residues of antibodies comprising SEQ ID Nos:19-58
- FIGs.4A-4B for paratope residues of antibodies comprising SEQ ID Nos:60-69
- FIGs.5A-5D for paratope residues of antibodies comprising SEQ ID NOs:71-106.
- Amino acid residues of a paratope contribute to an antibody’s interaction with an epitope of its target protein.
- An interaction can be a hydrogen bond, a salt bridge, a van der Waals interaction, an electrostatic interaction, a hydrophobic interaction, pi-interaction effects, an ionic bond, and/or any combination thereof.
- An interaction can be direct, or indirect, e.g., via a coordinated intermediate molecule, such as an ion or water.
- the residues of a paratope in some embodiments, comprise only residues that are part of a defined CDR. In some embodiments, the residues of a paratope further comprise one or more residues that are not part of a defined CDR (e.g., residues within a defined framework region).
- a paratope is oriented less than about 5.0 angstroms from an epitope on a target antigen when the polypeptide is bound to the target antigen, e.g., less than about: 4.5, 4.0, 3.5, 3.0, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0 or 0.9 angstroms, or about: 0.9-5.0, 0.9-4.8.1.0-5, 1.0-4.5, 1.0-4.0, 1.0-3.5, 1.1-3.5, 1.1-3.0, 1.2-3.0, 1.2-2.5, 1.3-2.5, 1.3-2.4, 1.4-2.4, 1.4-2.3, 1.5-2.3, 1.5-2.2, 1.6-2.2, 1.6-2.1, 1.7-2.1, 1.7-2.0 or 1.8-2.0 angstroms, from the epitope.
- all of the amino acid residues constituting the paratope are oriented less than about 5.0 angstroms from an epitope on a target antigen when the polypeptide is bound to the target antigen.
- less than all of the amino acid residues constituting the paratope (e.g., about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% of the amino acid residues)) in the paratope are oriented less than about 5.0 angstroms from an epitope on a target antigen when the polypeptide is bound to the target antigen.
- the term “substantially similar to” refers to a polypeptide disclosed herein that is substantially similar in amino acid sequence (e.g., has at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% of the amino acid residues amino acid sequence identity) and substantially preserves one or more functional properties of a specified polypeptide disclosed herein.
- the one or more functional properties are selected from, without limitation, a substantially similar binding affinity, a substantially similar - 36 - 3820371.v1 5708.1067001 binding specificity, a substantially similar inhibitory activity, a substantially similar neutralization activity, and a substantially similar self-association property.
- a polypeptide comprises a paratope that is substantially similar to a paratope of a polypeptide selected from any one of AB-1 to AB-76. In some embodiments, a polypeptide comprises a paratope comprising only conservative substitutions (e.g., only highly conservative substitutions) relative to a paratope of a polypeptide selected from any one of AB-1 to AB-76.
- a polypeptide comprises a paratope comprising up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 conservative substitutions (e.g., up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 highly conservative substitutions) relative to a paratope of a polypeptide selected from any one of AB-1 to AB-76.
- a polypeptide comprises a paratope having 100% sequence identity to a paratope of a polypeptide selected from any one of AB-1 to AB-76.
- a polypeptide comprises a paratope that is substantially similar to the paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:67 (AB-9);
- the paratope comprises amino acid residues corresponding to each of A50, X11 (position 54), X15 (position 59), and V106 of SEQ ID NO: 2 and D1, I2, Q27, Y32, Y49, Y50, F91, X20 (position 92), X21 (position 93), Y94 and P95 of SEQ ID NO: 59, or a subset thereof.
- a polypeptide comprising a paratope disclosed herein comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (V L ).
- the paratope residues are contained within the V H and V L of a polypeptide.
- a polypeptide comprises an immunoglobulin light chain variable region, an immunoglobulin heavy chain variable region, or an immunoglobulin light chain variable region and an immunoglobulin heavy chain variable region.
- a polypeptide comprises six CDRs of a polypeptide disclosed herein.
- a polypeptide has fewer than six (e.g., 1, 2, 3, 4 or 5) of the CDRs of a polypeptide disclosed herein.
- the disclosure provides a polypeptide that specifically binds PD-1, wherein the polypeptide comprises: a V H amino acid sequence comprising a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2) and a heavy chain complementarity determining region 3 (HCDR3) that are substantially similar in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216; and a VL amino acid sequence comprising a light chain complementarity determining region 1 (LCDR1), a light chain complementarity determining region 2 (LCDR2) and a light chain complementarity determining region 3 (LCDR3) that are substantially similar in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in any of S
- a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2 and an LCDR3 that substantially preserve one or more functional properties (e.g., binding to PD-1, PD-1 agonist activity, increased PD-1 signaling) of an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2 and an LCDR3 of a polypeptide selected from any one of AB-1 to AB-76.
- one or more functional properties e.g., binding to PD-1, PD-1 agonist activity, increased PD-1 signaling
- a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2 and an LCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2 and an LCDR3 of a polypeptide selected from any one of AB-1 to AB-76.
- a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2 and an LCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an HCDR1, - 40 - 3820371.v1 5708.1067001 an HCDR2, an HCDR3, an LCDR1, an LCDR2 and an LCDR3 of a polypeptide selected from any one of AB-1 to AB-76.
- a polypeptide disclosed herein comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2 and an LCDR3 having 100% sequence identity to an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2 and an LCDR3 of a polypeptide selected from any one of AB-1 to AB-76.
- a polypeptide comprises an HCDR1, an HCDR2 and an HCDR3, and an LCDR1, an LCDR2 and an LCDR3, of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:6 and SEQ
- a polypeptide comprises an HCDR1, an HCDR2 and an HCDR3, and an LCDR1, an LCDR2 and an LCDR3, of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); or SEQ ID NO:214 and SEQ ID NO:226 (AB-74).
- a polypeptide comprises an HCDR1, an HCDR2 and an HCDR3, and an LCDR1, an LCDR2 and an LCDR3, of an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:206 and a VL comprising the amino acid sequence of SEQ ID NO:217 (AB-65).
- a polypeptide comprises an HCDR1, an HCDR2 and an HCDR3, and an LCDR1, an LCDR2 and an LCDR3, of an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:215, and a V L comprising the amino acid sequence of SEQ ID NO:104 (AB-75).
- a polypeptide comprises an HCDR1, an HCDR2 and an HCDR3, and an LCDR1, an LCDR2 and an LCDR3, of an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:214, and a V L comprising the amino acid sequence of SEQ ID NO:226 (AB-74).
- a CDR (e.g., HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and/or LCDR3) can be a CDR defined by any art-recognized method for identifying CDR residues of an antibody, as described further herein (e.g., a CDR as defined by Kabat, a CDR as defined by Chothia, a CDR as defined by IMGT).
- a polypeptide comprises a paratope that is substantially similar to the paratope of an antibody comprising a V H /V L pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:67 (AB-9
- a polypeptide comprises a paratope that is identical to the paratope of an antibody comprising a V H /V L pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); - 46 - 3820371.v1 5708.1067001
- the disclosure also provides, among other things, a polypeptide comprising: - 48 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:227, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:229, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-65); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:148, an HCDR3 comprising the amino acid sequence of SEQ ID NO:228, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising:
- a polypeptide comprises: an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:227, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:229, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-65); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:148, an HCDR3 comprising the amino acid sequence of SEQ ID NO:228, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-75); or - 60
- a polypeptide comprises: a) an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, and an HCDR3 comprising the amino acid sequence of SEQ ID NO:227; and b) an LCDR 1 comprising the amino acid sequence of SEQ ID NO:229, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-65).
- a polypeptide comprises: a) an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:148, and an HCDR3 comprising the amino acid sequence of SEQ ID NO:228; and b) an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-75).
- a polypeptide comprises: a) an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, and an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, and b) an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-74).
- the disclosure provides a polypeptide that specifically binds PD-1, comprising a VH comprising: a) the amino acid sequence of SEQ ID NO:2, wherein: X 1 is L or F; X2 is G, A, S, T or P; X 3 is V, F or absent; X 4 is S or absent; - 61 - 3820371.v1 5708.1067001 X5 is S, G, N or absent; X6 is F, D, I, T, S or V; X 7 is A, S, R, N or K; X8 is A, H or T; X9 is M or I; X 10 is S or G; X 11 is S or G; X12 is S or G; X 13 is G, D, A, R, E or T; X 14 is H, D, A, S or N; X15 is A or I; X16 is H, A, I, Y or V; X 17 is S or D;
- polypeptides disclosed herein further comprise a VL.
- the polypeptide comprises a VL comprising: a) the amino acid sequence of SEQ ID NO:59, wherein: X20 is H, Q, A, S, Y, R or K; or X21 is A, S, T or G, or any combination of the foregoing; or b) the amino acid sequence of SEQ ID NO:70, wherein: X46 is V, I or F; X 47 is V, K, T, M, R or L; X 48 is P or T; X49 is P or Q; X50 is P, F or S; X 51 is P or S; X52 is V or L; X53 is H or Q; X 54 is D, G or Y; X 55 is D, T or N; X56 is C, Y or A; X 57 is K or E; X 58 is M, T, I or S; X59 is Y or S; X 60 is R, G, S or D; X 61 is R or S;
- SEQ ID NO:59 is a consensus VL sequence for SEQ ID Nos:60-69 herein
- SEQ ID NO:70 is a consensus V L sequence for SEQ ID Nos:71-106 herein.
- the disclosure provides a polypeptide that specifically binds PD-1, comprising a VH comprising the amino acid sequence of SEQ ID NO:2, wherein: X 1 is L or F; X 2 is G, A, S, T or P; X3 is V, F or absent; X4 is S or absent; X 5 is S, G, N or absent; X6 is F, D, I, T, S or V; X7 is A, S, R, N or K; X 8 is A, H or T; X 9 is M or I; X10 is S or G; X 11 is S or G; X 12 is S or G; X13 is G, D, A, R, E or T; X 14 is H, D, A, S or N; X 15 is A or I; X16 is H, A, I, Y or V; X17 is S or D; X 18 is Y, T or H; or X19 is A, Y or T
- polypeptides disclosed herein further a V L comprising the amino acid sequence of SEQ ID NO:59, wherein: X20 is H, Q, A, S, Y, R or K; or X 21 is A, S, T or G, or any combination of the foregoing.
- the disclosure provides a polypeptide that specifically binds PD-1, comprising a VH comprising the amino acid sequence of SEQ ID NO:18, wherein: X1 is V or E; X2 is L or I; X 3 is V or A; X 4 is G or S; X5 is H, Q or L; X 6 is P or L; X 7 is T or A; X8 is F, G or S; X9 is G, D or S; X 10 is Y, S or A; X11 is T, Y or A; X12 is L or I; X 13 is K, R or E; X 14 is V or M; X15 is V, T or I; X 16 is K, R, T or S; X 17 is C, G, Q or S; X18 is K, G or S; X 19 is G or S; X 20 is C or Y; X
- polypeptides disclosed herein comprises a V L comprising the amino acid sequence of SEQ ID NO:70, wherein: X 46 is V, I or F; X 47 is V, K, T, M, R or L; X48 is P or T; X 49 is P or Q; X 50 is P, F or S; X51 is P or S; X52 is V or L; X 53 is H or Q; X54 is D, G or Y; X55 is D, T or N; X 56 is C, Y or A; X 57 is K or E; X58 is M, T, I or S; X 59 is Y or S; X 60 is R, G, S or D; - 67 - 3820371.v1 5708.1067001 X61 is R or S; X62 is Y, I or F; X 63 is Y or S; X64 is V, R or T; X65 is T or S;
- a polypeptide disclosed herein comprises a VH that comprises an HCDR1, an HCDR2 and an HCDR3 that are substantially similar in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206- 216 (see Table 4 for SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216, and Table 6 for non-limiting examples of corresponding HCDR1, HCDR2 and HCDR3 sequences).
- a polypeptide comprises a V H that comprises an HCDR1, an HCDR2 and an HCDR3 that are substantially similar in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215 and SEQ ID NO:214.
- a polypeptide comprises a V H that comprises an HCDR1, an HCDR2 and an HCDR3 that are substantially similar in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in SEQ ID NO:206.
- a polypeptide comprises a V H that comprises an HCDR1, an HCDR2 and an HCDR3 that are substantially similar in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in SEQ ID NO:215.
- a polypeptide comprises a V H that comprises an HCDR1, an HCDR2 and an - 68 - 3820371.v1 5708.1067001 HCDR3 that are substantially similar in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in SEQ ID NO:214.
- a polypeptide disclosed herein comprises a V L that comprises an LCDR1, an LCDR2 and an LCDR3 that are substantially similar in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226 (see Table 5 for SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226, and Table 6 for non-limiting examples of corresponding LCDR1, LCDR2 and LCDR3 sequences).
- a polypeptide comprises a V L that comprises an LCDR1, an LCDR2 and an LCDR3 that are substantially similar in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104 and SEQ ID NO:226.
- a polypeptide comprises a VL that comprises an LCDR1, an LCDR2 and an LCDR3 that are substantially similar in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in SEQ ID NO:217.
- a polypeptide comprises a V L that comprises an LCDR1, an LCDR2 and an LCDR3 that are substantially similar in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in SEQ ID NO:104.
- a polypeptide comprises a V L that comprises an LCDR1, an LCDR2 and an LCDR3 that are substantially similar in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in SEQ ID NO:226.
- a polypeptide disclosed herein comprises a V H that comprises an HCDR1, an HCDR2 and an HCDR3 that are identical in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216 (see Table 4 for SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216, and Table 6 for non-limiting examples of corresponding HCDR1, HCDR2 and HCDR3 sequences).
- a polypeptide comprises a V H that comprises an HCDR1, an HCDR2 and an HCDR3 that are identical in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215 and SEQ ID NO:214.
- a polypeptide comprises a V H that comprises an HCDR1, an HCDR2 and an HCDR3 that are - 69 - 3820371.v1 5708.1067001 identical in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in SEQ ID NO:206.
- a polypeptide comprises a V H that comprises an HCDR1, an HCDR2 and an HCDR3 that are identical in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in SEQ ID NO:215.
- a polypeptide comprises a V H that comprises an HCDR1, an HCDR2 and an HCDR3 that are identical in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence set forth in SEQ ID NO:214.
- a polypeptide disclosed herein comprises a V L that comprises an LCDR1, an LCDR2 and an LCDR3 that are identical in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226 (see Table 5 for SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226, and Table 6 for non- limiting examples of corresponding LCDR1, LCDR2 and LCDR3 sequences).
- a polypeptide comprises a VL that comprises an LCDR1, an LCDR2 and an LCDR3 that are identical in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104 and SEQ ID NO:226.
- a polypeptide comprises a V L that comprises an LCDR1, an LCDR2 and an LCDR3 that are identical in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in SEQ ID NO:217.
- a polypeptide comprises a V L that comprises an LCDR1, an LCDR2 and an LCDR3 that are identical in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in SEQ ID NO:104.
- a polypeptide comprises a VL that comprises an LCDR1, an LCDR2 and an LCDR3 that are identical in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in SEQ ID NO:226.
- a polypeptide disclosed herein comprises a paratope that is substantially similar to a paratope of a V H/ V L combination selected from: a) SEQ ID NO:206/SEQ ID NO:217 (AB-65), SEQ ID NO:215/SEQ ID NO:104 (AB-75), SEQ ID NO:214/SEQ ID NO:226 (AB-74), SEQ ID NO:207/SEQ ID NO:218 (AB-66), SEQ ID NO:208/SEQ ID NO:219 (AB-67), SEQ ID NO:209/SEQ ID NO:220 (AB-68), SEQ ID NO:53/SEQ ID NO:221 (AB-69), - 70 - 3820371.v1 5708.1067001 SEQ ID NO:210/SEQ ID NO:222 (AB-70), SEQ ID NO:211/SEQ ID NO:223 (AB-71), SEQ ID NO:212/SEQ ID NO:224 (AB-72), SEQ ID NO:210/SEQ
- a polypeptide disclosed herein comprises a paratope that is identical to a paratope of a V H/ V L combination selected from: a) SEQ ID NO:206/SEQ ID NO:217 (AB-65), SEQ ID NO:215/SEQ ID NO:104 (AB-75), SEQ ID NO:214/SEQ ID NO:226 (AB-74), SEQ ID NO:207/SEQ ID NO:218 (AB-66), SEQ ID NO:208/SEQ ID NO:219 (AB-67), SEQ ID NO:209/SEQ ID NO:220 (AB-68), SEQ ID NO:53/SEQ ID NO:221 (AB-69), SEQ ID NO:210/SEQ ID NO:222 (AB-70), SEQ ID NO:211/SEQ ID NO:223 (AB-71), SEQ ID NO:212/SEQ ID NO:224 (AB-72), SEQ ID NO:213/SEQ ID NO:225 (AB-73), or
- a polypeptide disclosed herein comprises a paratope that differs from a paratope of a V H/ V L combination selected from: a) SEQ ID NO:206/SEQ ID NO:217 (AB-65), SEQ ID NO:215/SEQ ID NO:104 (AB-75), SEQ ID NO:214/SEQ ID NO:226 (AB-74), SEQ ID NO:207/SEQ ID NO:218 (AB-66), SEQ ID NO:208/SEQ ID NO:219 (AB-67), SEQ ID NO:209/SEQ ID NO:220 (AB-68), SEQ ID NO:53/SEQ ID NO:221 (AB-69), SEQ ID NO:210/SEQ ID NO:222 (AB-70), SEQ ID NO:211/SEQ ID NO:223 (AB-71), SEQ ID NO:212/SEQ ID NO:224 (AB-72), SEQ ID NO:213/SEQ ID NO:225 (AB-73), or
- a polypeptide disclosed herein comprises a V H that has at least about 70% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216.
- the V H can have at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206- 216.
- the V H has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216.
- a polypeptide comprises a V H that has at least about 70% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214.
- the VH can have at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214.
- the V H has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214.
- a polypeptide disclosed herein comprises a V H that has at least about 70% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in SEQ ID NO:206.
- the VH can have at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in SEQ ID NO:206.
- the V H has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a V H amino acid sequence set forth in SEQ ID NO:206.
- a polypeptide disclosed herein comprises a VH that has at least about 70% sequence identity to the amino acid sequence of a V H amino acid sequence set forth in SEQ ID NO:215.
- the V H can have at least about: 71%, 72%, 73%, - 75 - 3820371.v1 5708.1067001 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a V H amino acid sequence set forth in SEQ ID NO:215.
- the VH has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in SEQ ID NO:215.
- a polypeptide disclosed herein comprises a V H that has at least about 70% sequence identity to the amino acid sequence of a V H amino acid sequence set forth in SEQ ID NO:214.
- the VH can have at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in SEQ ID NO:214.
- the VH has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a V H amino acid sequence set forth in SEQ ID NO:214.
- a polypeptide disclosed herein comprises a VL that has at least about 70% sequence identity to the amino acid sequence of a VL amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226.
- the V L can be at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226.
- the VL has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226.
- a polypeptide comprises a VL that has at least about 70% sequence identity to the amino acid sequence of a VL amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226.
- the V L can be at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226.
- the VL has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226. - 76 - 3820371.v1 5708.1067001 [00103]
- a polypeptide comprises a VL that has at least about 70% sequence identity to the amino acid sequence of a VL amino acid sequence set forth in SEQ ID NO:217.
- the V L can be at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in SEQ ID NO:217.
- the V L has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in SEQ ID NO:217.
- a polypeptide comprises a V L that has at least about 70% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in SEQ ID NO:104.
- the VL can be at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a VL amino acid sequence set forth in SEQ ID NO:104.
- the VL has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a VL amino acid sequence set forth in SEQ ID NO:104.
- a polypeptide comprises a V L that has at least about 70% sequence identity to the amino acid sequence of a VL amino acid sequence set forth in SEQ ID NO:226.
- the V L can be at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in SEQ ID NO:226.
- the V L has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in SEQ ID NO:226.
- a polypeptide disclosed herein comprises a VH that comprises at least 1 amino acid substitution relative to the amino acid sequence of a V H amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- the VH comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a V H amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216.
- the at least 1 amino acid - 77 - 3820371.v1 5708.1067001 substitution replaces only an HCDR1, an HCDR2 and/or an HCDR3 residue, of a VH amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216.
- the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a VH amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216.
- a polypeptide comprises a V H that comprises at least 1 amino acid substitution relative to the amino acid sequence of a V H amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- the VH comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a VH amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214.
- the at least 1 amino acid substitution replaces only an HCDR1, an HCDR2 and/or an HCDR3 residue, of a VH amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a VH amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214.
- a polypeptide comprises a V H that comprises at least 1 amino acid substitution relative to the amino acid sequence of a VH amino acid sequence set forth in SEQ ID NO:206.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2- 19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- the VH comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a V H amino acid sequence set forth in SEQ ID NO:206.
- the at least 1 amino acid substitution replaces only an HCDR1, an HCDR2 and/or an HCDR3 residue, of a VH amino acid sequence set forth in SEQ ID NO:206. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a V H amino acid sequence set forth in SEQ ID NO:206.
- a polypeptide comprises a VH that comprises at least 1 amino acid substitution relative to the amino acid sequence of a V H amino acid sequence set forth in SEQ ID NO:215.
- the number of amino acid substitutions can be at least - 78 - 3820371.v1 5708.1067001 about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2- 19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- the V H comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a VH amino acid sequence set forth in SEQ ID NO:215.
- the at least 1 amino acid substitution replaces only an HCDR1, an HCDR2 and/or an HCDR3 residue, of a V H amino acid sequence set forth in SEQ ID NO:215. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a VH amino acid sequence set forth in SEQ ID NO:215.
- a polypeptide comprises a V H that comprises at least 1 amino acid substitution relative to the amino acid sequence of a V H amino acid sequence set forth in SEQ ID NO:214.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2- 19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- the VH comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a VH amino acid sequence set forth in SEQ ID NO:214.
- the at least 1 amino acid substitution replaces only an HCDR1, an HCDR2 and/or an HCDR3 residue, of a V H amino acid sequence set forth in SEQ ID NO:214.
- the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a V H amino acid sequence set forth in SEQ ID NO:214.
- the amino acid substitutions are conservative substitutions.
- conservative amino acid substitution(s) or “conservative substitution(s)” refers to an amino acid substitution having a value of 0 or greater in BLOSUM62.
- the amino acid substitutions are highly conservative substitutions.
- the term “highly conservative amino acid substitution(s)” or “highly conservative substitution(s)” refers to an amino acid substitution having a value of at least 1 (e.g., at least 2) in BLOSUM62.
- a polypeptide disclosed herein comprises a VL that comprises at least 1 amino acid substitution relative to the amino acid sequence of a VL amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2- 18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- the V L comprises about 1-10 amino acid substitutions, relative to the - 79 - 3820371.v1 5708.1067001 amino acid sequence of a VL amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226.
- the at least 1 amino acid substitution replaces only an LCDR1, an LCDR2 and/or an LCDR3 residue, of a V L amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226.
- the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a V L amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226.
- a polypeptide comprises a VL that comprises at least 1 amino acid substitution relative to the amino acid sequence of a V L amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- the V L comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a VL amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226.
- the at least 1 amino acid substitution replaces only an LCDR1, an LCDR2 and/or an LCDR3 residue, of a V L amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a V L amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226.
- a polypeptide comprises a V L that comprises at least 1 amino acid substitution relative to the amino acid sequence of a V L amino acid sequence set forth in SEQ ID NO:217.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2- 19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- the VL comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a VL amino acid sequence set forth in SEQ ID NO:217.
- the at least 1 amino acid substitution replaces only an LCDR1, an LCDR2 and/or an LCDR3 residue, of a V L amino acid sequence set forth in SEQ ID NO:217. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a V L amino acid sequence set forth in SEQ ID NO:217. - 80 - 3820371.v1 5708.1067001 [00116] In some embodiments, a polypeptide comprises a VL that comprises at least 1 amino acid substitution relative to the amino acid sequence of a VL amino acid sequence set forth in SEQ ID NO:104.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2- 19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- the V L comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a V L amino acid sequence set forth in SEQ ID NO:104.
- the at least 1 amino acid substitution replaces only an LCDR1, an LCDR2 and/or an LCDR3 residue, of a V L amino acid sequence set forth in SEQ ID NO:104.
- the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a VL amino acid sequence set forth in SEQ ID NO:104.
- a polypeptide comprises a VL that comprises at least 1 amino acid substitution relative to the amino acid sequence of a V L amino acid sequence set forth in SEQ ID NO:226.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2- 19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- the V L comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a VL amino acid sequence set forth in SEQ ID NO:226.
- the at least 1 amino acid substitution replaces only an LCDR1, an LCDR2 and/or an LCDR3 residue, of a V L amino acid sequence set forth in SEQ ID NO:226.
- a polypeptide comprises: a) an HCDR1 comprising at least 1 amino acid substitution relative to at least one amino acid sequence set forth in any one of SEQ ID NOs:107-126; b) an HCDR2 comprising at least 1 amino acid substitution relative to at least one amino acid sequence set forth in any one of SEQ ID NOs:127-150; c) an HCDR3 comprising at least 1 amino acid substitution relative to at least one amino acid sequence set forth in any one of SEQ ID NOs:151-171, SEQ ID NO:227, and SEQ ID NO:228; d) an LCDR1 comprising at least 1 amino acid substitution relative to at least one amino acid sequence set forth in any one of SEQ ID NOs:172-178 and SEQ ID NO:229; -
- a polypeptide disclosed herein comprises a V H that comprises an amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216.
- a polypeptide comprises a V H that comprises an amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214.
- a polypeptide comprises a VH that comprises an amino acid sequence set forth in SEQ ID NO:206.
- a polypeptide comprises a VH that comprises an amino acid sequence set forth in SEQ ID NO:215.
- a polypeptide comprises a VH that comprises an amino acid sequence set forth in SEQ ID NO:214.
- a polypeptide disclosed herein comprises a V L that comprises an amino acid sequence set forth in any of SEQ ID NOs:59-69, SEQ ID NOs:71- 106, and SEQ ID NOs:217-226.
- a polypeptide comprises a V L that comprises an amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226.
- a polypeptide comprises a VL that comprises an amino acid sequence set forth in SEQ ID NO:217.
- a polypeptide comprises a V L that comprises an amino acid sequence set forth in SEQ ID NO:104. In some embodiments, a polypeptide comprises a VL that comprises an amino acid sequence set forth in SEQ ID NO:226. [00123] In some embodiments, a polypeptide disclosed herein comprises: a V H comprising an amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216; and a VL comprising an amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226.
- a polypeptide comprises: a VH comprising an amino acid sequence set forth in any one of SEQ ID NO:53 and SEQ ID NOs:206-216; and - 82 - 3820371.v1 5708.1067001 a VL comprising an amino acid sequence set forth in any one of SEQ ID NO:104, SEQ ID NO:106, and SEQ ID NOs:217-226.
- a polypeptide comprises: a VH comprising an amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214; and a V L comprising an amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226.
- a polypeptide comprises: a V H comprising an amino acid sequence set forth in SEQ ID NO:206; and a V L comprising an amino acid sequence set forth in SEQ ID NO:217.
- a polypeptide comprises: a VH comprising an amino acid sequence set forth in SEQ ID NO:215; and a V L comprising an amino acid sequence set forth in SEQ ID NO:104.
- a polypeptide comprises: a VH comprising an amino acid sequence set forth in SEQ ID NO:214; and a V L comprising an amino acid sequence set forth in SEQ ID NO:226.
- a polypeptide disclosed herein comprises: a VH comprising an amino acid sequence set forth in any of SEQ ID NOs:3-17; and a V L comprising an amino acid sequence set forth in any of SEQ ID NOs:59-69.
- a polypeptide disclosed herein comprises: a VH comprising an amino acid sequence set forth in any of SEQ ID NOs:19-58; and a V L comprising an amino acid sequence set forth in any of SEQ ID NOs:71-106.
- a polypeptide disclosed herein comprises a V H and V L that are human.
- a polypeptide disclosed herein comprises a VH and VL that are humanized, contain human framework regions, or a combination thereof.
- a polypeptide disclosed herein is an immunoglobulin molecule, such as an antibody (e.g., a whole antibody, an intact antibody) or an antigen- binding fragment of an antibody.
- a polypeptide disclosed herein is an antibody.
- the term “antibody” refers to an immunoglobulin molecule capable of specific binding to a target, such as a carbohydrate, polynucleotide, lipid, polypeptide, etc., through at least one antigen recognition site, located in the variable domain of the immunoglobulin molecule.
- the term “antibody” refers to a full-length antibody. - 83 - 3820371.v1 5708.1067001
- a polypeptide disclosed herein is a single-domain antibody or an antigen-binding fragment thereof.
- single-domain antibody refers to an immunoglobulin molecule consisting of a single monomeric variable antibody domain and capable of specific binding to a target.
- the single- domain antibody can be of any species, such as a murine antibody, a human antibody or a humanized single-domain antibody.
- a polypeptide disclosed herein is a heavy-chain antibody comprising two or more heavy chains, but lacking light chains, or an antigen-binding fragment thereof.
- heavy chain antibodies include camelid Vhh (also referred to as VHH or V H H) antibodies.
- Camelid antibodies are antibodies from the Camelidae family of mammals that include llamas, camels, and alpacas.
- a polypeptide disclosed herein is an antibody comprising two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds or multimers thereof (for example, IgM).
- Each heavy chain comprises a heavy chain variable domain (VH) and a heavy chain constant domain (comprising domains CH1, hinge CH2 and CH3).
- Each light chain comprises a light chain variable domain (V L ) and a light chain constant domain (CL).
- V H and the V L regions may be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed within framework regions (FR).
- CDR complementarity determining regions
- FR framework regions
- V H and V L each comprises three CDRs and four FR segments, arranged from the amino-terminus to the carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
- the antibody can be of any species, such as a murine antibody, a human antibody or a humanized antibody.
- the extent of the framework region and the CDRs of an antibody can be identified using one of several suitable methodologies that are well known in the art, for example, by the Kabat definition, the Chothia definition, the AbM definition, and/or the contact definition.
- a “CDR” encompasses any CDR defined by an art-recognized method for identifying the CDR residues on an antibody. See, e.g., Kabat, E.A., et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No.91-3242, Chothia et al., (1989) Nature 342:877; Chothia, C. et al., (1987) J. Mol. Biol.196:901-917; Al-lazikani et al., (1997) J. Molec. Biol. 273:927-948; and Almagro, J. Mol.
- a polypeptide disclosed herein is an antigen-binding fragment of an antibody.
- the term “antigen-binding fragment” refers to a portion of an immunoglobulin molecule (e.g., antibody) that retains the antigen binding properties of the full-length antibody.
- Non-limiting examples of antigen-binding fragments include a VH region, a V L region, an Fab fragment, an F(ab’) 2 fragment, an Fd fragment, an Fv fragment, and a domain antibody (dAb) consisting of one V H domain or one V L domain, etc.
- V H and V L domains may be linked together via a synthetic linker to form various types of single-chain antibody designs in which the V H /V L domains pair intramolecularly, or intermolecularly in those cases when the V H and V L domains are expressed by separate chains, to form a monovalent antigen binding site, such as single chain Fv (scFv) or diabody.
- a polypeptide disclosed herein is an antigen binding fragment selected from Fab, F(ab’) 2 , Fab’, scFv, or Fv. In some embodiments, a polypeptide is a scFv. [00140] In some embodiments, a polypeptide disclosed herein is a modified or engineered antibody. Examples of modified or engineered antibodies include chimeric antibodies, multiparatopic antibodies (e.g., biparatopic antibodies), and multispecific antibodies (e.g., bispecific antibodies).
- multispecific antibodies e.g., bispecific antibodies
- targets or, where relevant, their receptors IL-1beta, IL-1RA, IL-2, IL4, IL-5, IL-13, IL-18, IL-23, IL-36, CLTA-4, OX40, GITR, BTLA, VISTA, TNF-alpha and other TNF family or TNF receptor family members, interferon-beta or interferon-gamma.
- multiparatopic antibody means an antibody that comprises at least two single domain antibodies, in which at least one single domain antibody is directed against a first antigenic determinant on an antigen and at least one other single domain antibody is directed against a second antigenic determinant on the same antigen.
- a “biparatopic” antibody comprises at least one single domain antibody directed against a first antigenic determinant on an antigen and at least one further single domain antibody directed against a second antigenic determinant on the same antigen.
- multispecific antibody means an antibody that comprises at least two single domain antibodies, in which at least one single domain antibody is directed against a first antigen and at least one other single domain antibody is directed against a second antigen (different from the first antigen).
- a “bispecific” antibody is one that comprises at least one single domain antibody directed against a first antigen and at least one further single domain antibody directed against a second antigen, e.g., different from the first antigen.
- a polypeptide is an antibody mimetic.
- antibody mimetic refers to polypeptides capable of mimicking an antibody’s ability to bind an antigen, but structurally differ from native antibody structures.
- Non-limiting examples of antibody mimetics include Adnectins, Affibodies, Affilins, Affimers, Affitins, Alphabodies, Anticalins, Avimers, DARPins, Fynomers, Kunitz domain peptides, monobodies, nanobodies, nanoCLAMPs, and Versabodies.
- a polypeptide disclosed herein competes with a reference antibody for binding to a full-length PD-1 (e.g., SEQ ID NO:1).
- a polypeptide disclosed herein comprises: a) an antibody heavy chain constant domain sequence; b) an antibody light chain constant domain sequence; or c) both an antibody heavy chain constant domain sequence and an antibody light chain constant domain sequence.
- a polypeptide disclosed herein comprises an antibody heavy chain constant domain sequence.
- the antibody heavy chain constant domain is selected from the group consisting of an IgA constant domain, an IgD - 86 - 3820371.v1 5708.1067001 constant domain, an IgE constant domain, an IgG constant domain and an IgM constant domain.
- the IgG constant domain is an IgG1 constant domain, an IgG2 constant domain, an IgG3 constant domain or an IgG4 constant domain.
- the IgG2 constant domain is an IgG2a, an IgG2b constant domain or an IgG2c constant domain.
- the IgA constant domain is an IgA1 constant domain or an IgA2 constant domain.
- the antibody heavy chain constant domain is an IgG2 constant domain.
- a polypeptide disclosed herein comprises an immunoglobulin light chain variable domain (V L ).
- V L immunoglobulin light chain variable domain
- the V H and V L domains may be linked together via a linker (e.g., a synthetic linker) to form various types of single-chain antibody designs in which the VH/VL domains pair intramolecularly, or intermolecularly in those cases when the VH and VL domains are expressed by separate chains, to form a monovalent antigen binding site.
- a polypeptide disclosed herein comprises an antibody light chain constant domain sequence.
- the antibody light chain constant domain is selected from the group consisting of a ⁇ constant domain and a ⁇ constant domain.
- the antibody heavy chain constant domain is an IgG2 constant domain, and the antibody light chain constant domain is a ⁇ constant domain.
- the antibody heavy chain constant domain sequence has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:202.
- the antibody heavy chain constant domain sequence can have at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:202.
- the antibody heavy chain constant domain sequence has at least about 70% or at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:202.
- SEQ ID NO:202 The sequence identified as SEQ ID NO:202 is shown below: [00150] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPP CPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQP REPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTFPPMLDS - 87 - 3820371.v1 5708.1067001 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSPGK (SEQ ID NO:202).
- the antibody light chain constant domain sequence has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:203 or SEQ ID NO:204.
- the antibody light chain constant domain sequence can have at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:203 or SEQ ID NO:204.
- the antibody light chain constant domain sequence has at least about 70% or at least about 80% sequence identity to SEQ ID NO:203 or SEQ ID NO:204.
- the sequences identified as SEQ ID NO:203 or SEQ ID NO:204 are shown below: [00152] RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:203).
- an antibody heavy chain constant domain sequence comprises at least 1 amino acid substitution relative to the amino acid sequence of SEQ ID NO:202.
- an antibody heavy chain constant domain sequence comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:202.
- an antibody light chain constant domain sequence comprises at least 1 amino acid substitution relative to the amino acid sequence of SEQ ID NO:203 or SEQ ID NO:204.
- an antibody light chain constant domain sequence comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:203 or SEQ ID NO:204. - 88 - 3820371.v1 5708.1067001 [00156] In some embodiments, an antibody light chain constant domain sequence comprises at least 1 amino acid substitution relative to the amino acid sequence of SEQ ID NO:203.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- the antibody light chain constant domain sequence comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:203.
- one or more amino acid substitutions are conservative substitutions.
- one or more amino acid substitutions are highly conservative substitutions.
- a polypeptide disclosed herein is an isolated polypeptide.
- the isolated polypeptide is recombinantly produced. In some embodiments, the isolated polypeptide is synthetically produced.
- a polypeptide disclosed herein is linked to a second polypeptide.
- the term “linked” means attached, via a covalent or noncovalent interaction. Conjugation can employ a suitable linking agent. Non-limiting examples include peptide linkers, compound linkers, and chemical cross-linking agents. In some embodiments, the linker is a disulfide bond.
- a polypeptide disclosed herein is conjugated to a heterologous moiety. The term “conjugated” refers to attached, via a covalent or noncovalent interaction.
- the heterologous moiety is a therapeutic agent, a diagnostic agent or a combination thereof.
- the heterologous moiety is polyethylene glycol (PEG), hexadecanoic acid, hydrogels, nanoparticles, multimerization domains and carrier peptides.
- PEG polyethylene glycol
- the nanoparticle is a lipid nanoparticle.
- the nanoparticle is a polymer nanoparticle.
- the polymer is an amphiphilic polymer.
- the polymer is a hydrophobic or hydrophilic polymer.
- Non-limiting examples of polymers include poly(lactic acid)- poly(ethylene glycol), poly(lactic-co-glycolic acid)-poly(ethylene glycol), poly(lactic-co- glycolic) acid (PLGA), poly(lactic-co-glycolic acid)-d- ⁇ -tocopheryl polyethylene glycol succinate, poly(lactic-co-glycolic acid)-ethylene oxide fumarate, poly(glycolic acid)- - 89 - 3820371.v1 5708.1067001 poly(ethylene glycol), polycaprolactone-poly(ethylene glycol), or any salts thereof.
- the polymer nanoparticle comprises poly(lactic-co-glycolic) acid (PLGA).
- the carrier polypeptide is albumin or an Fc polypeptide.
- a polypeptide described herein comprises an Fc polypeptide, or Fc domain (e.g., an IgG1 domain, an IgG2 domain or an IgG4 domain).
- the Fc domain comprises a mutation that for example, decreases (e.g., inhibits, ablates) an effector function of the Fc domain, increases half-life of an antibody or antibody fragment that comprises the Fc domain, or a combination thereof.
- an Fc domain comprises an LS modification (M428L/N434S substitutions with numbering determined by Kabat) or a YTE modification (i.e., M252Y/S254T/T256E substitutions as determined by Kabat numbering). In some embodiments, an Fc domain comprises a YTE modification.
- a polypeptide binds PD-1 with a binding constant (K D ) of about 100 pM or less.
- K D binding constant
- affinity constant is a measure of the extent of a reversible association between two molecular species (e.g., antibody and target protein) and includes both the actual binding affinity as well as the apparent binding affinity.
- Binding affinity can be determined using methods known in the art including, for example, by measurement of surface plasmon resonance, e.g., using a Biolayer interferometry (Octet, ForteBio) or a surface plasmon resonance (Biacore) system and assay.
- a Biolayer interferometry Octet, ForteBio
- a surface plasmon resonance Biacore
- a reference that compares various surface technologies for measuring binding affinity and kinetics is Yang, D., Singh, A., Wu, H., & Kroe-Barrett, R., Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics, Analytical Biochemistry 508: 78-96 (2016), the contents of which are incorporated by reference herein in their entirety.
- a polypeptide disclosed herein competes with one or more other antibodies disclosed herein for binding to a PD-1 protein (e.g., SEQ ID NO:1). Techniques and assays for assessing competition between antibodies are known in the art. - 90 - 3820371.v1 5708.1067001 Fusion Proteins [00166] In some embodiments, the disclosure provides a fusion protein comprising one or more of polypeptides described herein. [00167] The term “fusion protein” refers to a synthetic, semi-synthetic or recombinant single protein molecule.
- a fusion protein can comprise all or a portion of two or more different proteins and/or polypeptides that are attached by covalent bonds (e.g., peptide bonds).
- a fusion protein can comprise a full-length polypeptide disclosed herein (e.g., a whole antibody), or a fragment thereof (e.g., an antigen-binding fragment of an antibody).
- the heterologous partner can be a full-length protein or a fragment thereof (e.g., a truncated protein).
- Fusion proteins can be produced recombinantly or synthetically, using routine methods and reagents that are well known in the art.
- a fusion protein can be produced recombinantly in a suitable host cell (e.g., bacteria) according to methods known in the art. See, e.g., Current Protocols in Molecular Biology, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992; and Molecular Cloning: a Laboratory Manual, 2nd edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press.
- a nucleic acid molecule comprising a nucleotide sequence encoding a fusion protein described herein can be introduced and expressed in suitable host cell (e.g., E.
- the expressed fusion protein can be isolated/purified from the host cell (e.g., in inclusion bodies) using routine methods and readily available reagents.
- DNA fragments coding for different protein sequences e.g., a light-responsive domain, a heterologous peptide component
- the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.
- PCR amplification of nucleic acid fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive nucleic acid fragments that can subsequently be annealed and re-amplified to generate a chimeric nucleic acid sequence (see Ausubel et al., Current Protocols in Molecular Biology, 1992).
- the disclosure provides one or more polynucleotides (e.g., DNA, RNA, or analogs of either, e.g., optionally including one or more modified nucleotides; the polynucleotide may be linear or circular, e.g., linear or circular RNA) encoding any one - 91 - 3820371.v1 5708.1067001 of the polypeptides or fusion proteins described herein.
- polypeptides or fusion proteins disclosed herein is encoded by a single polynucleotide.
- polypeptides or fusion proteins disclosed herein is encoded by multiple polynucleotides.
- the polynucleotide comprises a nucleotide sequence that is codon-optimized for a chosen host cell.
- the disclosure provides a vector (e.g., an expression vector, including a viral-delivery vector) comprising any one or more of the polynucleotides described herein.
- expression vector refers to a replicable nucleic acid from which one or more proteins can be expressed when the expression vector is transformed into a suitable expression host cell.
- the vector (e.g., expression vector) comprises an expression control polynucleotide sequence operably linked to the polynucleotide, a polynucleotide sequence encoding a selectable marker, or both.
- the expression control polynucleotide sequence comprises a promoter sequence, an enhancer sequence, or both.
- the expression control polynucleotide sequence comprises an inducible promoter sequence.
- promoter refers to a region of DNA to which RNA polymerase binds and initiates the transcription of a gene.
- operably linked means that the nucleic acid is positioned in the recombinant polynucleotide, e.g., vector, in such a way that enables expression of the nucleic acid under control of the element (e.g., promoter) to which it is linked.
- element e.g., promoter
- selectable marker element is an element that confers a trait suitable for artificial selection. Selectable marker elements can be negative or positive selection markers.
- the disclosure provides an expression host cell comprising any one or more of the polynucleotides or expression vectors described herein.
- expression host cell refers to a cell useful for receiving, maintaining, reproducing and/or amplifying a vector.
- Non-limiting examples of expression host cells include mammalian cells such as hybridoma cells, Chinese hamster ovary (CHO) cells, COS cells, human embryonic kidney (HEK), yeast cells such as Pichia pastoris cells, or bacterial cells such as E. coli, including DH5 ⁇ , etc. - 92 - 3820371.v1 5708.1067001 Compositions [00177] In some embodiments, the disclosure provides a composition comprising any one of the polypeptides or fusion proteins described herein. In some embodiments, the composition is a pharmaceutical composition.
- the composition (e.g., pharmaceutical composition) comprises pharmaceutically acceptable carriers, excipients, stabilizers, diluents or tonifiers (Remington's Pharmaceutical Sciences 16 th edition, Osol, A. Ed. (1980)). Suitable pharmaceutically acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed.
- Non-limiting examples of pharmaceutically acceptable carriers, excipients, stabilizers, diluents or tonifiers include buffers (e.g., phosphate, citrate, histidine), antioxidants (e.g., ascorbic acid or methionine), preservatives, proteins (e.g., serum albumin, gelatin or immunoglobulins); hydrophilic polymers, amino acids, carbohydrates (e.g., monosaccharides, disaccharides, glucose, mannose or dextrins); chelating agents (e.g., EDTA), sugars (e.g., sucrose, mannitol, trehalose or sorbitol), salt- forming counter-ions (e.g., sodium), metal complexes (e.g., Zn-protein complexes); non-ionic surfactants (e.g., Tween), PLURONICSTM and polyethylene glycol (PEG).
- buffers e.g., phosphate, citrate,
- the composition (e.g., pharmaceutical composition) disclosed herein is formulated for a suitable administration schedule and route.
- administration routes include oral, rectal, mucosal, intravenous, intramuscular, subcutaneous and topical, etc.
- the composition (e.g., pharmaceutical composition) disclosed herein is stored in the form of an aqueous solution or a dried formulation (e.g., lyophilized).
- the composition is formulated to be administered by infusion (e.g., intravenous infusion).
- the composition is formulated to be administered with a second therapeutic agent as a combination therapy.
- the second therapeutic agent reduces (e.g., decreases, inhibits) an immune response, such as an inflammatory response. In some embodiments, the second therapeutic agent promotes immune tolerance.
- a polypeptide or composition disclosed herein is used in conjunction with other immune modulators, such as immune modulators that target aberrant T- or B-cell responses with complementary or orthogonal mechanisms, in a multispecific (e.g., bispecific) molecule (e.g., antibody) or co-administered format.
- Such agents include, for example, molecules modulating the following targets or, where relevant, their receptors: - 93 - 3820371.v1 5708.1067001 IL-1beta, IL-1RA, IL-2, IL4, IL-5, IL-13, IL-18, IL-23, IL-36, CLTA-4, OX40, GITR, BTLA, VISTA, TNF-alpha and other TNF family or TNF receptor family members, interferon-beta or interferon-gamma.
- Non-limiting examples of second therapeutic agents that are useful in combination with polypeptides and compositions described herein include disease-modifying anti- rheumatic drugs (DMARs), anti-TNF agents, TNF-Fcs, non-steroidal anti-inflammatory drugs (NSAIDs), Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), corticosteroids (e.g., glucocorticoids), therapeutic Treg cells, autophagy-related (ATG) proteins, ⁇ -l-guluronic acid (ALG), interferons, anti-inflammatory interleukins (e.g., IL-2, IL- 10), macrolides and biologics (e.g., dupilumab).
- DMARs disease-modifying anti- rheumatic drugs
- anti-TNF agents e.g., TNF-Fcs
- NSAIDs non-steroidal anti-inflammatory drugs
- ImSAIDs Immune Selective Anti-Inflammatory Derivatives
- second therapeutic agents that are useful in combination with polypeptides and compositions described herein include an insulin preparation (e.g., human insulin, insulin glargine, insulin lispro, insulin detemir, or insulin aspart), a sulfonylurea agent (e.g., glibenclamide, gliclazide, or glimepiride), a quick-acting insulin secretion promoter (e.g., nateglinide), a biguanide preparation (e.g., metformin), an insulin sensitizer (e.g., pioglitazone), an alpha-glucosidase inhibitor (e.g., acarbose or voglibose), a diabetic neuropathy therapeutic agent (e.g., epalrestat, mexiletine, or imidapril), a GLP-1 analog preparation (e.g., liraglutide, exenatide, or lixisenatide),
- the disclosure provides a method of modulating (e.g., inhibiting) PD-1 signaling in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier - 94 - 3820371.v1 5708.1067001 and, wherein as an active ingredient, any one of the polypeptides or fusion proteins described herein.
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier - 94 - 3820371.v1 5708.1067001 and, wherein as an active ingredient, any one of the polypeptides or fusion proteins described herein.
- subject and “patient” are used herein interchangeably to refer to an animal (e.g., a mammal, such as a human) who is to be treated according to a method disclosed herein.
- a subject to be treated according to methods described herein may be one who has been diagnosed with inflammation, such as inflammation associated with an inflammatory bowel disease (IBD) and/or autoimmune disease. Diagnosis may be performed by any method or technique known in the art. One skilled in the art will understand that a subject to be treated according to the present disclosure may have been subjected to standard tests or may have been identified, without examination, as one at risk due to the presence of one or more risk factors associated with the disease or condition. [00185] In some embodiments, the subject is a mammal.
- the subject is a mammal selected from the group consisting of a dog, a cat, a mouse, a rat, a hamster, a guinea pig, a horse, a pig, a sheep, a cow, a chimpanzee, a macaque, a cynomolgus, and a human.
- the subject is a primate.
- the subject is a human.
- the subject is 18 years of age or older, for example, about: 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 or 80 years of age or older. In some embodiments, the subject is 65 years of age or older.
- the subject is about: 18-80, 20-80, 20-75, 25-75, 25-70, 30-70, 30-65, 35-65, 35-60, 40-60, 40-55, 45-55 years of age. In some embodiments, the subject is about 18-65 years of age. [00187] In some embodiments, the subject is about 18 years of age or younger. In some embodiments, the subject is about: 16, 14, 12, 10, 8, 6, 4 or 2 years of age or older. In some embodiments, the subject is two years of age or older, for example, about: 2-18, 3-18, 3-16, 4-16, 4-14, 5-14, 5-12, 6-12, 6-10 or 8-10 years of age. [00188] In some embodiments, methods disclosed herein are useful for treating inflammation.
- methods disclosed herein are useful for treating an inflammatory disease, condition, or disorder.
- inflammatory diseases, conditions, or disorders include inflammatory bowel diseases (IBD) (e.g., Crohn’s disease, ulcerative colitis, and other forms of colitis or inflammation along the digestive tract thought to be caused by aberrant T-or B-cell biology), asthma and airway inflammation, autoimmune diseases (e.g., idiopathic autoimmune conditions), graft-versus-host disease - 95 - 3820371.v1 5708.1067001 (GvHD), and other conditions with aberrant T- or B-cell biology manifest as anti-self clinical syndromes.
- IBD inflammatory bowel diseases
- autoimmune diseases e.g., idiopathic autoimmune conditions
- graft-versus-host disease - 95 - 3820371.v1 5708.1067001 (GvHD) graft-versus-host disease - 95 - 3820371.v1 5708.1067001
- GvHD graft-versus-
- Non-limiting examples of autoimmune diseases that can be treated using the compositions and methods described herein include achalasia, Addison’s disease, adult Still's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti- GBM/anti-TBM nephritis, antiphospholipid syndrome, atopic dermatitis and other autoimmune dermatologic or mixed dermatologic-rheumatologic syndromes, autoimmune angioedema, autoimmune dermatitis, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune urticaria, axonal and neuronal neuropathy (AMAN), Baló disease, Behcet’s disease, benign mucosal pemphigoid
- treating refers to the medical management of a subject with the intent to improve, ameliorate, stabilize (i.e., not worsen), prevent or cure a disease, pathological condition, or disorder—such as the particular indications exemplified herein.
- This term includes active treatment (treatment directed to improve the disease, pathological condition, or disorder), causal treatment (treatment directed to the cause of the associated disease, pathological condition, or disorder), palliative treatment (treatment designed for the relief of symptoms), preventative treatment (treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder); and supportive treatment (treatment employed to supplement another therapy).
- Treatment also includes diminishment of the extent of the disease or condition; preventing spread of the disease or condition; delay or slowing the progress of the disease or condition; amelioration or palliation of the disease or condition; and remission (whether partial or total), whether detectable or undetectable.
- “Ameliorating” or “palliating” a disease or condition - 97 - 3820371.v1 5708.1067001 means that the extent and/or undesirable clinical manifestations of the disease, disorder, or condition are lessened and/or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment.
- Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
- a therapeutically effective amount is an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result (e.g., treatment, healing, inhibition or amelioration of physiological response or condition, etc.).
- the therapeutic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations.
- a therapeutically effective amount may vary according to factors such as disease state, age, sex, and weight of a mammal, mode of administration and the ability of a therapeutic, or combination of therapeutics, to elicit a desired response in an individual.
- Desired response or desired results include effects at the cellular level, tissue level, or clinical results.
- “a therapeutically effective amount” or synonym thereto depends upon the context in which it is being applied. For example, in some embodiments it is an amount of the composition sufficient to achieve a treatment response as compared to the response obtained without administration of the composition. In some embodiments, it is an amount that results in a beneficial or desired result in a subject as compared to a control.
- a therapeutically effective amount of a composition disclosed herein may be readily determined by one of ordinary skill by routine methods known in the art. Dosage regimen and route of administration may be adjusted to provide the optimum therapeutic response.
- a therapeutic agent described herein can be administered via a variety of routes of administration, including, for example, topical, transdermal, parenteral (e.g., intra-arterial, intravenous, intramuscular, subcutaneous injection, intradermal injection), intravenous infusion and inhalation (e.g., intrabronchial, intranasal or oral inhalation, intranasal drops) routes of administration, depending on the compound and the particular disease to be treated.
- parenteral e.g., intra-arterial, intravenous, intramuscular, subcutaneous injection, intradermal injection
- intravenous infusion and inhalation e.g., intrabronchial, intranasal or oral inhalation, intranasal drops
- a polypeptide, composition, or pharmaceutical composition disclosed herein is administered to a subject as a monotherapy. - 98 - 3820371.v1 5708.1067001 [00195] In some embodiments, a polypeptide, composition, or pharmaceutical composition disclosed herein is administered to a subject in combination with one or more additional therapeutic agents (e.g., concurrently or sequentially with one or more additional therapeutic agents). In some embodiments, a subject has been previously treated with one or more therapeutic agents prior to being administered a polypeptide, composition, or pharmaceutical composition disclosed herein.
- the method comprises administering a therapeutically effective amount of one or more additional therapeutic agents to the subject at the same time as, or following administration of a polypeptide, composition, or pharmaceutical composition disclosed herein.
- the subject previously received a therapeutic agent.
- Administration of the two or more therapeutic agents encompasses co- administration of the therapeutic agents in a substantially simultaneous manner, such as in a pharmaceutical combination.
- such administration encompasses co- administration in multiple containers, or separate containers (e.g., capsules, powders, and liquids) for each therapeutic agent.
- Such administration also encompasses use of each type of therapeutic agent in a sequential manner, either at approximately the same time or at different times.
- composition described herein and the second therapeutic agent can be administered via the same administration route or via different administration routes.
- Administration can be local or systemic as indicated.
- the preferred mode of administration can vary depending on the particular compound chosen.
- the disclosure provides, among other things, a method of increasing (e.g., enhancing, promoting) binding of PD-L1 and/or PD-L2 to PD-1 in a cell, comprising contacting the cell an effective amount of any one of the polypeptides or fusion proteins described herein.
- the disclosure provides, among other things, a method of inhibiting PD-1 signaling in a cell (e.g., a T cell), comprising contacting the cell an effective amount of any one of the polypeptides or fusion proteins described herein.
- a cell e.g., a T cell
- all terms of art, notations and other scientific terms or terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this disclosure pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art.
- the conjunctive term “and/or” between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by “and/or,” a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together.
- the description “at least 1, 2, 3, 4, or 5” also describes, inter alia, the ranges 1-2, 1-3, 1-4, 1-5, 2-3, 2-4, 2-5, 3-4, 3-5, and 4-5, et cetera.
- Headings used in this application are for convenience only and do not affect the interpretation of this application.
- Preferred features of each of the aspects or embodiments provided by the invention are applicable to all of the other aspects or embodiments of the invention mutatis mutandis and, without limitation, are exemplified by the dependent claims and also encompass combinations and permutations of individual features (e.g., elements, including numerical ranges and exemplary embodiments) of some embodiments and aspects of the invention, including the working examples.
- each of the combinations A-E, A-F, B- D, B-E, B-F, C-D, C-E, and C-F are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D.
- any subset or combination of these is also specifically contemplated and disclosed.
- the sub-groups of A-E, B-F, and C-E are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D.
- PD-1 plays a role in mediating immune homeostasis and T cell tolerance by inhibiting T cell receptor (TCR) signaling [1-3]. While antagonizing PD-1 has been a common approach in oncology, agonizing PD-1 is a relatively underexplored approach for ameliorating auto-immune disease. For example, mice deficient of PD-1 have been shown to spontaneously develop autoimmune disorders such as a lupus-like disease, suggesting an important role of PD-1 signaling in the regulation of autoimmunity [1, 4]. Activation of PD-1 leads to a downregulation of PD-1 expression, reduced cytokine release, and suppression of immune response, representing a promising treatment for autoimmune diseases.
- TCR T cell receptor
- Agonistic activity of an antibody is driven by targeting specific epitopes on the target, which Applicant identified.
- PD-1 antagonist antibodies such as Pembrolizumab and Nivolumab disrupt PD-1 binding with its natural ligands PD-L1 and PD-L2
- PD-1 agonist antibodies show no competition with PD-L1 or PD- L2, indicating that they bound a distinct epitope space on PD-1.
- binding agonist epitopes leads to crosslinking of PD-1 on the surface of T cells and elicits an immune inhibitory signaling pathway.
- MCS magnetic-activated cell sorting
- FACS fluorescence-activated cell sorting
- Antibodies were formatted into full-length human immunoglobulin 1 (IgG1) by subcloning the variable heavy (V H ) chain and variable light (V L ) chains into mammalian expression vectors containing corresponding constant regions (SEQ ID NO:202 and SEQ ID NO:203) using conventional methods. Each IgG protein was expressed in ExpiCHO cells following manufacturer’s methods (Thermo Fisher Scientific, Waltham, MA).
- Binding kinetics and affinity to PD-1 were measured with Bio-layer interferometry (BLI) using a ForteBio (Fremont, CA) Octet Red96e instrument or surface plasmon resonance (SPR) using a CARTERRA ® (Andover, MA) LSATM instrument.
- the SPR data are shown in Tables 1-3. Binding to PD-1 expressed on Raji cells was assessed by flow cytometry using an Intellicyt (Albuquerque, NM) iQue3 instrument (Table 1).
- an engineered Jurkat cell line expressing both PD-1 and a luciferase reporter driven by an NFAT response element was used.
- binding Kinetics & Functional Characterization of PD-1 Agonistic Antibodies [00214] a) Structural characterization of clone AB-49 [00215] The structure of AB-49 alone (without the antigen) was solved using X-ray crystallography, at 2.46 A resolution. The structure is shown in FIG.6B, with - 103 - 3820371.v1 5708.1067001 superimposition onto the corresponding computational model in FIG.6D. There is close agreement between the model and experimental structure (i.e., backbone RMSD over all CDR residues is 1.6 ⁇ , despite the fact that the comparison is between a Fab-only crystal structure and a computational model of the antibody in the bound state).
- Binding to PD-1 expressed on Jurkat cell cells was assessed by flow cytometry using an Intellicyt iQue3 instrument.
- PD-1 agonism was assessed in vitro using the same engineered Jurkat cell line expressing both PD-1 and a luciferase reporter driven by an NFAT response element (Promega, Madison, WI).
- KD binding affinity
- NFAT response element Promega, Madison, WI
- AB-58 to AB-64 were further optimized computationally and expressed as full- length IgG and expressed in Expi293 cells.
- the hits were functionally characterized for on- cell binding and TCR inhibition as described previously with one change: Jurkat cells expressing PD-1 were used to assess on-cell binding instead.
- Overall, computationally optimized hits showed 2-fold improvement in TCR inhibition (Table 3).
- - 105 - 3820371.v1 5708.1067001 Table 3.
- Functional Characterization of PD-1 Agonistic Antibodies Example 3.
- PBMC-Based Assay to Measure PD-1 Agonist Effects Peripheral blood mononuclear cells (PBMCs) are stimulated with anti-CD3 and anti-CD28 T cell activators prior to incubation with an anti-PD1 antibody disclosed herein.
- PD-1 agonist activity is measured by detecting a decrease in PD-1 surface expression, inhibition of T cell proliferation in a CD4 + T cell population, and/or reduction of secreted cytokines (e.g., TNF ⁇ and IFN ⁇ ) in the cell supernatant as a result of antibody treatment.
- cytokines e.g., TNF ⁇ and IFN ⁇
Abstract
L'invention concerne, dans divers modes de réalisation, des polypeptides (par exemple, des anticorps et des fragments de liaison à l'antigène de ceux-ci) qui se lient spécifiquement à la protéine de mort cellulaire programmée 1 (PD-1). L'invention concerne également, dans divers modes de réalisation, des protéines de fusion comprenant un polypeptide décrit ici, des polynucléotides codant pour un polypeptide décrit ici, des vecteurs et des cellules hôtes appropriés pour exprimer des polypeptides décrits ici, et des méthodes de traitement d'une maladie ou d'une affection (par exemple, un cancer) à l'aide de polypeptides décrits ici.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263402410P | 2022-08-30 | 2022-08-30 | |
US63/402,410 | 2022-08-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024050421A2 true WO2024050421A2 (fr) | 2024-03-07 |
WO2024050421A3 WO2024050421A3 (fr) | 2024-04-11 |
Family
ID=88068688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/073172 WO2024050421A2 (fr) | 2022-08-30 | 2023-08-30 | Molécules de liaison à l'antigène ciblant la protéine 1 de mort cellulaire programmée (pd-1) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024050421A2 (fr) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060919A2 (fr) | 2000-12-12 | 2002-08-08 | Medimmune, Inc. | Molecules a demi-vies longues, compositions et utilisations de celles-ci |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
AR114127A1 (es) * | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
-
2023
- 2023-08-30 WO PCT/US2023/073172 patent/WO2024050421A2/fr unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060919A2 (fr) | 2000-12-12 | 2002-08-08 | Medimmune, Inc. | Molecules a demi-vies longues, compositions et utilisations de celles-ci |
Non-Patent Citations (19)
Title |
---|
"Remington's Pharmaceutical Sciences", 1980 |
AL-LAZIKANI ET AL., J. MOLEC. BIOL, vol. 273, 1997, pages 927 - 948 |
ALMAGRO, J. MOL. RECOGNIT, vol. 17, 2004, pages 132 - 143 |
AUSUBEL ET AL., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY |
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1992, JOHN WILEY & SONS |
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 |
CHOTHIA, C. ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
DUMET ET AL.: "Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development", MABS, vol. 11, no. 8, 2019, pages 1341 - 50, XP055732501, DOI: 10.1080/19420862.2019.1664365 |
FRANCISCO ET AL.: "The PD-1 pathway in tolerance and autoimmunity", IMMUNOL REV, vol. 236, 2010, pages 219 - 42, XP002616816, DOI: 10.1111/j.1600-065X.2010.00923.x |
GREBINOSKIVIGNALI: "Inhibitory receptor agonists: the future of autoimmune disease therapeutics?", CURR OPIN IMMUNOL, vol. 67, 2020, pages 1 - 9, XP086407348, DOI: 10.1016/j.coi.2020.06.001 |
KABAT, E.A ET AL.: "Sequences of Proteins of Immunological Interest", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES |
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 |
NISHIMURA ET AL.: "Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIMmotif-carrying immunoreceptor", IMMUNITY, vol. 11, no. 2, 1999, pages 141 - 51, XP000971788, DOI: 10.1016/S1074-7613(00)80089-8 |
PEARSONLIPMAN, PROC. NAT'L. ACAD. SCI. USA, vol. 85, 1988, pages 2444 |
QIN ET AL.: "The Diverse Function of PD-1/PD-L Pathway Beyond Cancer", FRONT IMMUNOL, vol. 10, 2019, pages 2298, XP055670804, DOI: 10.3389/fimmu.2019.02298 |
SAMBROOK ET AL.: "Molecular Cloning: a Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
SMITHWATERMAN, ADV. APPL. MATH, vol. 2, 1981, pages 482 |
VERED KUNIK ET AL., NUCLEIC ACIDS RESEARCH, vol. 40, 1 July 2012 (2012-07-01), pages W521 - W524 |
YANG, DSINGH, AWU, HKROE-BARRETT, R: "Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics", ANALYTICAL BIOCHEMISTRY, vol. 508, 2016, pages 78 - 96, XP029642360, DOI: 10.1016/j.ab.2016.06.024 |
Also Published As
Publication number | Publication date |
---|---|
WO2024050421A3 (fr) | 2024-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210403593A1 (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
US11649285B2 (en) | Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy | |
KR102344901B1 (ko) | 항-FcRn 항체 | |
JP2023129543A (ja) | 抗cd73抗体およびそれらの使用方法 | |
JP2020501531A (ja) | 新規抗cd137抗体およびその使用 | |
US20160272707A1 (en) | Vstm5 antibodies, and uses thereof for treatment of cancer, infectious diseases and immune related diseases | |
JP2019502656A (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
JP7459058B2 (ja) | Cd137/her2二重特異性物質とpd-1系阻害物質とを含む併用療法およびその使用法 | |
CN111902428B (zh) | 一种双特异性抗体及其用途 | |
TWI612059B (zh) | 泛-ELR<sup>+</sup>CXC趨化因子抗體 | |
CN110546163A (zh) | 抗-tigit抗原结合蛋白及其使用方法 | |
KR20210030925A (ko) | 메소텔린 및 cd137 결합 분자 | |
KR20210078517A (ko) | 중증근무력증의 치료 방법 | |
JP2019505785A5 (fr) | ||
RU2770209C2 (ru) | Терапевтические антитела против лиганда cd40 | |
JP2021530428A (ja) | 頭頸部癌の処置 | |
WO2024050421A2 (fr) | Molécules de liaison à l'antigène ciblant la protéine 1 de mort cellulaire programmée (pd-1) | |
WO2019160979A1 (fr) | Anticorps monoclonaux bispécifiques à base de fcrn thérapeutiques | |
US20220227873A1 (en) | Anti-gal9 immune-inhibiting binding molecules | |
JP7422070B2 (ja) | 癌の治療のための配合剤 | |
JP2023510429A (ja) | 抗ガレクチン-9抗体およびその使用 | |
JP2019505516A (ja) | インターロイキン−17(il−17)アンタゴニストを使用してざ瘡を治療する方法 | |
US20230406943A1 (en) | Methods for treating inflammatory skin conditions | |
US20230140694A1 (en) | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies | |
CN116059377A (zh) | 抗ox40抗体在联合用药中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23772077 Country of ref document: EP Kind code of ref document: A2 |